预约演示
更新于：2025-08-10
Methenamine Hippurate
马尿酸乌洛托品
更新于：2025-08-10
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1967-07-05), |
最高研发阶段(中国)撤市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C15H21N5O3 |
InChIKeyROAIXOJGRFKICW-UHFFFAOYSA-N |
CAS号5714-73-8 |
关联
15
项与 马尿酸乌洛托品 相关的临床试验NCT06710899
Does Vitamin C Improve the Efficacy of Methenamine Hippurate (Hiprex®) in Prophylaxis of Recurrent Urinary Tract Infections? A Proof of Concept Study
CTR20252444
马尿酸乌洛托品片在中国健康受试者中单次空腹/餐后口服给药、随机、开放、单中心、两制剂、两序列、两周期、交叉生物等效性试验
NCT06953271
Methenamine Hippurate Compared to Typical Antibiotic Prophylaxis in the Prevention of Urinary Tract Infection Following Intradetrusor OnabotulinumtoxinA Injection for Treatment of Overactive Bladder: a Randomized Controlled Non-Inferiority Trial
100 项与 马尿酸乌洛托品 相关的临床结果
登录后查看更多信息
100 项与 马尿酸乌洛托品 相关的转化医学
登录后查看更多信息
100 项与 马尿酸乌洛托品 相关的专利（医药）
登录后查看更多信息
512
项与 马尿酸乌洛托品 相关的文献（医药）2025-09-01JOURNAL OF MOLECULAR BIOLOGY
A key region of Tau that is able to drive assembly and modulate inhibition by Hydromethylthionine
Article
作者: Rickard, Janet E ; Serpell, Louise C ; Simpson, Michael ; Al-Hilaly, Youssra K ; Harrington, Charles R ; Storey, John M D ; Wischik, Claude M
Tau297-391 (dGAE) forms paired helical filaments in vitro that resemble those deposited in Alzheimer's disease brain tissue. We have previously shown that hydromethylthionine (HMT) has the ability to inhibit dGAE self-assembly at sub-stoichiometric ratios. Here, we examined two regions of tau within the core filament-forming region that possess high self-assembly propensity sequences and have explored their ability to form filaments and whether their self-assembly can be inhibited by HMT. We confirm that tau306-323 self-assembles to form filaments but that fibrillogenesis is not inhibited by HMT. Previous work by others has shown that tau350-362 (PAM4) forms assemblies that recapitulate the C-shaped structure of paired helical filaments. Here, a chiral spectral circular dichroism fingerprint shows that HMT binds to tau350-362 and we reveal that HMT inhibits assembly. We conclude that the region important for assembly and inhibition is formed by the inner C-shaped region of tau and suggest that the central region involved in filament assembly may associate with HMT to prevent self-assembly.
2025-07-01CLINICAL MICROBIOLOGY AND INFECTION
Methenamine hippurate as prophylaxis for recurrent urinary tract infections in older women—a triple-blind, randomised, placebo-controlled, phase IV trial (ImpresU)
Article
作者: Sundvall, Pär-Daniel ; Verheij, Theo J M ; Åhrén, Christina ; Lindbæk, Morten ; Lithén, Sara Sofia ; Høye, Sigurd ; Platteel, Tamara N ; Godycki-Cwirko, Maciej ; Groen, Wim G ; Kowalczyk, Anna ; Sundvall, Sofia ; Grude, Nils ; Heltveit-Olsen, Silje Rebekka ; Hertogh, Cees M P M ; Arnljots, Egill Snaebjörnsson ; Gunnarsson, Ronny
OBJECTIVES:
This study aims to investigate the preventive effect of the antiseptic methenamine hippurate on recurrent urinary tract infections (rUTIs) in older women.
METHODS:
Triple-blind, randomised, placebo-controlled phase IV trial with a 6-month treatment period and a 6-month follow-up. Women ≥70 years with rUTIs were recruited from general practice in Norway, Sweden, Poland, and The Netherlands. Recruitment started in December 2019, with follow-up completed at the end of June 2023. Participants were randomly assigned to methenamine hippurate 1g × 2 or placebo 1 tablet × 2 for 6 months. The primary outcome was the number of antibiotic treatments for urinary tract infections (UTIs) during the treatment period. Secondary outcomes included the number of antibiotic treatments for UTIs during the follow-up period, UTI symptom severity and episode duration. Differences in complications were measured as safety outcomes.
RESULTS:
Of 289 recruited women, 281 (97%) were included in the main analysis (140 in the methenamine hippurate group, 141 in the placebo group). During the treatment period, the methenamine hippurate group had a lower incidence of antibiotic treatments for UTIs than the placebo group, with an incidence rate ratio of 0.75 (95% CI: 0.57-1.0, p 0.049). In the follow-up period, the ratio was reversed: the methenamine hippurate group had a higher incidence of antibiotic treatments for UTIs than the placebo group, with an incidence rate ratio of 1.7 (95% CI:1.3-2.3, p<0.001). There were no important differences in UTI symptom severity/duration or complications between the groups.
DISCUSSION:
Methenamine hippurate reduces the frequency of rUTIs in older women with a point estimate of a 25% reduction, suggesting advantages over low-dose antibiotic prophylaxis because of its low potential for selection for antimicrobial resistance and mild side effects. However, discontinuation after 6-month treatment duration seems to increase the risk of UTI relapses, and physicians should be aware of this risk when initiating or discontinuing treatment.
TRIAL REGISTRATION NUMBER:
ClinicalTrials.gov Registry (NCT04077580); EudraCT: 2018-002235.
2025-06-01PHYTOCHEMICAL ANALYSIS
HPLC Fingerprint Combined With Chemometrics and Multicomponent Content Determination for Quality Evaluation and Control of Huangma Tincture
Article
作者: Shang, Si‐yang ; Qiu, Jing ; Leng, Jing ; Zhou, Peng ; Li, Jie
ABSTRACT:
Introduction:
Huangma Tincture (HMT) is a Chinese patent medicine with a history of clinical use for more than 60 years, widely used for treating dermal chronic ulcer such as diabetic foot ulcer. However, the overall quality evaluation and control method of HMT has not yet been researched.
Objective:
The aim of this study is to establish a comprehensive quality evaluation and control method for HMT based on high‐performance liquid chromatography (HPLC) fingerprint, chemometrics, and multicomponent content determination.
Methods:
Establishing chemical fingerprint of HMT and carrying out similarity analysis comprehensively reflect the consistency of the formulation in terms of chemical composition. Chemometrics analyses, including hierarchical cluster analysis (HCA), principal component analysis (PCA), and orthogonal partial least squares‐discriminant analysis (OPLS‐DA), were performed to identify components crucial to quality differences. The content of five potential bioactive ingredients (brucine, strychnine, jatrorrhizine, coptisine, and berberine hydrochloride) was determined as a supplementary quality control measure.
Results:
HPLC fingerprint of HMT with similarity index > 0.990 was established, in which five common compounds (brucine, strychnine, jatrorrhizine, coptisine, and berberine hydrochloride) were identified. HCA, PCA, and OPLS‐DA results, validated through 200 permutation tests, were basically consistent. The contents of brucine, strychnine, jatrorrhizine, coptisine, and berberine hydrochloride in 20 batches of HMT samples were 0.2088–0.5556, 0.2599–0.9868, 0.1358–0.2092, 0.2634–0.6843, and 1.8301–2.7826 mg/mL, respectively.
Conclusion:
HPLC fingerprint combined with chemometrics and multicomponent content determination considering both effect and toxicity provides a robust method for the comprehensive quality evaluation and control of HMT.
7
项与 马尿酸乌洛托品 相关的新闻（医药）
100 项与 马尿酸乌洛托品 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 泌尿道感染 | 美国 | 1976-09-09 | |
| 感染 | 美国 | 1967-07-05 | |
| 下尿路症状 | 中国 | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 185 | (Methenamine Hippurate With Cranberry) | 廠廠鬱鬱鑰窪齋壓範積 = 鬱積選鬱願膚糧築獵窪 製範襯憲蓋構淵範壓蓋 (衊齋範範遞襯積廠蓋鹹, 簾鏇襯築壓壓淵窪製網 ~ 膚餘齋廠簾願鬱壓憲淵) 更多 | - | 2022-11-14 | ||
Placebo tablet (Placebo With Cranberry) | 廠廠鬱鬱鑰窪齋壓範積 = 獵蓋製觸範壓襯膚顧範 製範襯憲蓋構淵範壓蓋 (衊齋範範遞襯積廠蓋鹹, 膚膚鏇鑰築糧鏇鏇選範 ~ 壓積夢願膚範夢範夢膚) 更多 | ||||||
临床2期 | 185 | Methenamine hippurate with cranberry capsules | 繭範醖觸齋顧遞鏇壓積(廠鏇襯顧襯餘構壓窪築) = Overall adherence and level of satisfaction was high 衊衊網簾醖壓膚壓選膚 (鹹願壓願簾鏇構鹹鑰願 ) 更多 | 积极 | 2022-03-01 | ||
Cranberry with placebo | |||||||
N/A | 201 | (Methenamine) | 積顧遞鬱積壓選鹹繭鹹 = 鹹獵艱簾蓋膚積襯遞構 築獵顧鏇範積遞膚衊築 (膚糧餘窪繭膚蓋鬱膚襯, 鹽憲繭襯網膚積積壓鬱 ~ 選願鏇願簾願製獵齋積) 更多 | - | 2022-02-25 | ||
(Ciprofloxacin) | 積顧遞鬱積壓選鹹繭鹹 = 顧齋憲觸艱遞願壓築夢 築獵顧鏇範積遞膚衊築 (膚糧餘窪繭膚蓋鬱膚襯, 窪鹽簾淵窪鹽夢憲鹹鹽 ~ 鹹廠鹽淵鏇夢獵製鹽壓) 更多 | ||||||
临床4期 | 92 | (Patients With Recurrent UTIs Arm 1) | 鏇齋艱選餘顧蓋範廠鏇(糧簾鏇築鹹簾鑰選鹹襯) = 選醖淵願壓壓廠餘觸餘 鏇網膚鏇鹹網製餘簾壓 (鬱廠壓網繭觸網觸壓鹹, 84.4) 更多 | - | 2020-01-14 | ||
(Patients With Recurrent UTIs Arm 2) | 鏇齋艱選餘顧蓋範廠鏇(糧簾鏇築鹹簾鑰選鹹襯) = 築襯鏇淵範築淵衊築襯 鏇網膚鏇鹹網製餘簾壓 (鬱廠壓網繭觸網觸壓鹹, 94) 更多 | ||||||
临床4期 | 2,032 | 獵艱願範鬱簾繭蓋窪範(窪築遞壓餘艱範獵餘觸): RR = 0.56 (95% CI, 0.37 ~ 0.83) 更多 | - | 2012-10-17 | |||
(Control/No treatment) | |||||||
临床4期 | 64 | Trimethoprim 100 mg | 憲構壓蓋淵願壓鏇壓餘(選構獵糧夢壓繭衊膚淵) = 築齋襯觸糧淵範網憲選 範製齋艱鬱遞鬱築淵醖 (糧顧簾願範繭蓋選齋醖 ) | - | 1983-12-01 | ||
憲構壓蓋淵願壓鏇壓餘(選構獵糧夢壓繭衊膚淵) = 鑰膚夢糧窪夢顧遞膚夢 範製齋艱鬱遞鬱築淵醖 (糧顧簾願範繭蓋選齋醖 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用